Venmax Drugs & Pharmaceuticals Ltd
Incorporated in 1998, Venmax Drugs & Pharmaceuticals Ltd is engaged in the business of IT & ITES services[1]
- Market Cap ₹ 13.3 Cr.
- Current Price ₹ 25.4
- High / Low ₹ 30.9 / 0.00
- Stock P/E
- Book Value ₹ 8.42
- Dividend Yield 0.00 %
- ROCE -0.96 %
- ROE -0.53 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 3.02 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 23.1%
- Company has high debtors of 428 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.59 | 2.43 | 1.93 | 0.26 | 0.00 | 0.15 | 0.47 | 0.17 | 0.00 | 0.00 | 0.00 | 0.81 | |
1.02 | 2.54 | 2.07 | 0.88 | 0.23 | 0.38 | 0.72 | 0.50 | 0.12 | 0.19 | 0.11 | 1.87 | |
Operating Profit | -0.43 | -0.11 | -0.14 | -0.62 | -0.23 | -0.23 | -0.25 | -0.33 | -0.12 | -0.19 | -0.11 | -1.06 |
OPM % | -72.88% | -4.53% | -7.25% | -238.46% | -153.33% | -53.19% | -194.12% | -130.86% | ||||
-1.32 | 0.00 | 0.00 | -0.72 | 0.00 | 0.00 | 0.00 | 0.18 | 1.98 | 0.42 | 0.20 | 1.05 | |
Interest | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Profit before tax | -1.77 | -0.11 | -0.14 | -1.34 | -0.24 | -0.24 | -0.26 | -0.16 | 1.85 | 0.22 | 0.08 | -0.02 |
Tax % | 29.38% | -36.36% | 0.00% | 0.00% | 0.00% | 0.00% | 3.85% | 0.00% | 0.00% | 0.00% | 25.00% | 0.00% |
-2.30 | -0.08 | -0.14 | -1.34 | -0.24 | -0.24 | -0.27 | -0.16 | 1.85 | 0.23 | 0.06 | -0.01 | |
EPS in Rs | -4.39 | -0.15 | -0.27 | -2.56 | -0.46 | -0.46 | -0.52 | -0.31 | 3.53 | 0.44 | 0.11 | -0.02 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -10% |
5 Years: | 12% |
3 Years: | % |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | 6% |
5 Years: | 14% |
3 Years: | % |
TTM: | -117% |
Stock Price CAGR | |
---|---|
10 Years: | 19% |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | -1% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 |
Reserves | -4.82 | -4.90 | -5.04 | -7.11 | -7.35 | -7.59 | -7.86 | -8.03 | -6.18 | -5.95 | -5.89 | -0.83 |
1.40 | 1.50 | 1.72 | 1.85 | 2.04 | 2.24 | 2.52 | 2.33 | 0.35 | 0.35 | 0.35 | 0.05 | |
0.92 | 1.85 | 0.68 | 0.16 | 0.14 | 0.44 | 0.56 | 0.76 | 0.80 | 0.57 | 0.38 | 0.71 | |
Total Liabilities | 2.74 | 3.69 | 2.60 | 0.14 | 0.07 | 0.33 | 0.46 | 0.30 | 0.21 | 0.21 | 0.08 | 5.17 |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.10 | 0.09 | 0.08 | 0.07 | 0.07 | 0.04 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
2.73 | 3.68 | 2.59 | 0.14 | 0.07 | 0.22 | 0.36 | 0.21 | 0.13 | 0.14 | 0.01 | 5.13 | |
Total Assets | 2.74 | 3.69 | 2.60 | 0.14 | 0.07 | 0.33 | 0.46 | 0.30 | 0.21 | 0.21 | 0.08 | 5.17 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.85 | -0.10 | -0.19 | -1.06 | -0.26 | -0.05 | -0.28 | 0.26 | 1.91 | 0.00 | 0.00 | -2.29 | |
1.43 | 0.00 | 0.00 | 0.01 | 0.00 | -0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
-2.28 | 0.10 | 0.22 | 1.02 | 0.26 | 0.16 | 0.28 | -0.19 | -1.98 | 0.00 | 0.00 | 4.77 | |
Net Cash Flow | 0.00 | 0.00 | 0.03 | -0.03 | 0.00 | 0.00 | 0.00 | 0.07 | -0.07 | 0.00 | 0.00 | 2.48 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 129.92 | 21.03 | 128.60 | 0.00 | 0.00 | 31.06 | 85.88 | 428.09 | ||||
Inventory Days | 468.30 | 225.44 | 0.00 | 0.00 | 446.11 | 250.94 | 0.00 | 27.72 | ||||
Days Payable | 75.75 | 251.51 | 1,257.22 | 456.25 | 291.08 | |||||||
Cash Conversion Cycle | 522.46 | -5.04 | 128.60 | 0.00 | -811.11 | -174.25 | 85.88 | 164.73 | ||||
Working Capital Days | 420.68 | -3.00 | 5.67 | -126.35 | -535.33 | -155.32 | -1,331.18 | 874.20 | ||||
ROCE % | -10.08% | -6.01% | -7.45% | -52.63% | -0.96% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
10 May - Listing Regulations, 2015, enclosed here with copies of Newspaper publications providing Audited financial results for the Quarter and Year ended March 31st, 2025.
-
Integrated Filing (Financial)
9 May - Audited FY25 results with Rs.507.25L preferential warrants allotment to non-promoters.
- Audited Financial Results March 31St 2025. 9 May
-
Board Meeting Outcome for Board Meeting Outcome For Audited Financial Results For The Quarter And Year Ended March 31St, 2025.
9 May - Venmax Drugs reports FY25 audited results; slight loss, preferential warrant allotment proceeds Rs.507.25 lakhs.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
5 May - Venmax confirms it is not a 'Large Corporate' as per SEBI criteria as of 31 March 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
a) VDPL is focused on establishing chain of Medical Stores with a brand name Ananya Pharma under the Venmax Drugs & Pharma Ltd, with the backing support of Formulations plant (Suzichem Labs). Currently, it has established 3 Shops & planning to expand them to 50 numbers around Hyderabad.
b) The company is developing oncology products in R&D. It is planning to establish a manufacturing UNIT with cGMP facility at Pharma Cluster at Hyderabad, to meet the export demand.